文献速递真实世界研究与卫生经济流行病学与生物统计

同类品牌药竞争与价格:系统综述证据

Competition and price among brand-name drugs in the same class: A systematic review of the evidence.
PubMed 文献 · PLoS Med · 2019-07-30

该研究系统检索1990至2019年PubMed和EconLit,纳入10项关于美国市场同类品牌药竞争的实证研究。未发现任何研究显示品牌间竞争能降低已上市药品的标价;部分研究提示竞争可能制约新药定价,但受药品相对质量和营销影响。结论认为仅靠促进同类品牌竞争难以降低标价,需结构性改革。

要点

  • 未发现同类品牌药竞争能降低已上市药品标价的证据。
  • 品牌竞争可能影响新药定价,但受相对疗效和营销强度调节。
  • 加速批准非首创新药等政策若无结构改革,可能不会降低标价。

核心结论

  • 促进同类品牌药竞争的政策,如加速批准非首创新药,若无额外结构改革,可能不会降低药品标价。

研究设计与样本

  • 系统综述检索PubMed和EconLit,纳入1990年1月至2019年4月发表的10项美国市场品牌药竞争实证研究。

主要发现

  • 纳入研究覆盖降压药、抗感染药、ADHD中枢兴奋剂、多发性硬化疾病修饰疗法、H2受体拮抗剂、TNF抑制剂、抗癌药及所有上市或新药等类别。
  • 无研究报告同类品牌竞争降低已上市药品标价。
  • 2项研究提示品牌竞争可能有助于制约新药定价。
  • 其他研究提示竞争效应受竞争药品相对质量和营销程度影响,更安全有效的新药及更强营销与更高同类标价相关。

临床怎么用

  • 评估促进品牌竞争政策时,应认识到其可能无法降低已上市药品标价,需结合结构性改革。

局限性

  • 纳入研究使用标价而非净价。
  • 部分数据较陈旧。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Some experts have proposed combating rising drug prices by promoting brand-brand competition, a situation that is supposed to arise when multiple US Food and Drug Administration (FDA)-approved brand-name products in the same class are indicated for the same condition. However, numerous reports exist of price increases following the introduction of brand-name competition, suggesting that it may not be effective. We performed a systematic literature review of the peer-reviewed health policy and economics literature to better understand the interplay between new drug entry and intraclass drug prices. METHODS AND FINDINGS: We searched PubMed and EconLit for original studies on brand-brand competition in the US market published in English between January 1990 and April 2019. We performed a qualitative synthesis of each study's data, recording its primary objective, methodology, and results. We found 10 empirical investigations, with 1 study each on antihypertensives, anti-infectives, central nervous system stimulants for attention deficit/hyperactivity disorder, disease-modifying therapies for multiple sclerosis, histamine-2 (H2) blockers, and tumor necrosis factor (TNF) inhibitors; 2 studies on cancer medications; and 2 studies on all marketed or new drugs. None of the studies reported that brand-brand competition lowers list prices of existing drugs within a class. The findings of 2 studies suggest that such competition may help restrain how new drug prices are set. Other studies found evidence that brand-brand competition was mediated by the relative quality of competing drugs and the extent to which they are marketed, with safer or more effective new drugs and greater marketing associated with higher intraclass list prices. Our investigation was limited by the studies' use of list rather than net prices and the age of some of the data. CONCLUSIONS: Our findings suggest that policies to promote brand-brand competition in the US pharmaceutical market, such as accelerating approval of non-first-in-class drugs, will likely not result in lower drug list prices absent additional structural reforms.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Sarpatwari A, DiBello J, Zakarian M, et al. Competition and price among brand-name drugs in the same class: A systematic review of the evidence. PLoS Med. 2019. PMID: 31361747. doi:10.1371/journal.pmed.1002872

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。